biostudies-literatureLabrador JInstituto de Salud Carlos III1734https://www.ebi.ac.uk/biostudies/studies/S-EPMC8997036biostudies-literatureUnknown14(7)The effectiveness of venetoclax (VEN) in relapsed or refractory acute myeloid leukemia (RR-AML) has not been well established. This retrospective, multicenter, observational database studied the effectiveness of VEN in a cohort of 51 RR-AML patients and evaluated for predictors of response and overall survival (OS). The median age was 68 years, most were at high risk, 61% received ≥2 therapies for AML, 49% had received hypomethylating agents, and ECOG was ≥2 in 52%. Complete remission (CR) rate, including CR with incomplete hematological recovery (CRi), was 12.4%. Additionally, 10.4% experienced partial response (PR). The CR/CRi was higher in combination with azacitidine (AZA; 17.9%) than with decitabine (DEC; 6.7%) and low-dose cytarabine (LDAC; 0%). Mutated NPM1 was associated with increCancersUse of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience.PMC8997036CD21/00022Conde-Royo DFoncillas MARecio IGarcia-Fortes MCuello RSanz MAde Laiglesia AVall-Llovera FOlivier CSeri-Merino CVives SMunoz-Garcia CBienert-Garcia Ade Miguel DVidriales MBBenzo-Callejo GSayas MJLabrador JPerez-Encinas MSanchez-Sanchez MJTormo MMartinez-Cuadron DVahi MColorado MMontesinos PRodriguez-Medina CRoldan-Perez ASaiz-Rodriguez MfalseUse of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience.The effectiveness of venetoclax (VEN) in relapsed or refractory acute myeloid leukemia (RR-AML) has not been well established. This retrospective, multicenter, observational database studied the effectiveness of VEN in a cohort of 51 RR-AML patients and evaluated for predictors of response and overall survival (OS). The median age was 68 years, most were at high risk, 61% received ≥2 therapies for AML, 49% had received hypomethylating agents, and ECOG was ≥2 in 52%. Complete remission (CR) rate, including CR with incomplete hematological recovery (CRi), was 12.4%. Additionally, 10.4% experienced partial response (PR). The CR/CRi was higher in combination with azacitidine (AZA; 17.9%) than with decitabine (DEC; 6.7%) and low-dose cytarabine (LDAC; 0%). Mutated NPM1 was associated with incre2022-01-01T00:00:00Z2022 Mar2026-06-18T03:14:50.827Z2025-04-04T12:40:59.55ZS-EPMC89970363540651210.3390/cancers14071734